Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company. The new company is included in key SIX market indices and has an investment-grade credit…
Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women’s trajectories through college and career entry. The…
Gilead Sciences, announced that Kevin E Lofton, Lead Independent Director, has been named one of the most influential leaders in corporate governance by the NACD (National Association of Corporate Directors) as part of their 2023 NACD Directorship 100™, an annual…
Bagsværd, Denmark and Boston, Massachusetts, US, 25 September 2023 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation…
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular…
CHICAGO, IL – Sept. 20, 2023 – GE HealthCare (Nasdaq: GEHC) today released its inaugural Sustainability Report, which describes the steps the Company has taken to establish its stand-alone environmental, social, and governance (ESG) practice and infrastructure, as well as…
THOUSAND OAKS, Calif., Sept. 20, 2023 – Amgen today announced the launch of Amgen Partners of Choice, a new network that brings together Amgen’s oncology research and development experts and world-class clinical leaders at eight research centers across the globe.…
👉 Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in clinical trials.1,2,3,4 👉 With approximately 100,000 people newly diagnosed with…
These critical initiatives come as the global healthcare company confirms its commitment to positively impact society by tackling climate change and its consequences for human health. Ramping up adaptation efforts and initiatives to address the impact of climate change on the health of…
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. Ojjaara is…